FDA Clearance Tracker · P170032-S019
Woven EndoBridge Aneurysm Embolization (WEB) System
Last checked: Nov 20, 2026Latest source record: Mar 20, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Mar 20, 2026
Approved
Time to decision
260 days
Received Jul 3, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P170032-S019
- Device name
- Woven EndoBridge Aneurysm Embolization (WEB) System
- Applicant
- MicroVention, Inc.
- Applicant location
- Aliso Viejo, CA
- Received
- Jul 3, 2025
- Decided
- Mar 20, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P170032
Device type
- Device type
- Intrasaccular Flow Disruption Device (OPR)
- Device class
- Class III
- Specialty
- Neurology & Neurosurgery
FDA's approval statement
As written in FDA's record.
Approval of the revised protocol for the PAS1 PostMarket Surveillance-Long Term Safety post-approval study.
Source documents
Other decisions for MicroVention, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K254035 · Decided Sep 3, 2026 · 261 days after receipt
Device type: Aspiration Thrombectomy Catheter (QEZ) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.